Tekcapital plc Belluscura Files Additional Patent
19 Février 2019 - 9:52AM
RNS Non-Regulatory
TIDMTEK
Tekcapital plc
19 February 2019
19(th) February 2019
Tekcapital plc
("Tekcapital" or the "Company")
Belluscura Files Additional Patent
Tekcapital plc (AIM: TEK), the UK intellectual property (IP)
investment group focused on creating marketplace value from
university technology, announces that its portfolio company
Belluscura plc ("Belluscura") in conjunction with its exclusive
research partner Separation Design Group, has expanded its oxygen
therapy technology with the filing of a broad patent application
covering oxygen enrichment inventions relating to a portable
artificial lung and wound care devices.
The latest patent application, titled "Improved Extracorporeal
Membrane Oxygenation Device, System and Related Methods," involves
incorporating and expanding their existing oxygen enrichment patent
portfolio into an innovative, next generation portable artificial
lung and a novel wound care treatment device.
Commenting on the patenting activities, Bob Rauker, CEO of
Belluscura, said: "We are very excited about our next generation
oxygen technology. With the anticipated launch of our X-PLOR(TM)
portable oxygen concentrator later this year into the respiratory
treatment field where over 250 million people suffer from chronic
obstructive pulmonary disease (COPD), the third leading cause of
death, it is critical that we continue to innovate into the
ever-expanding oxygen therapy market."
Dr. Clifford Gross, Chairman at Tekcapital commented: "We are
delighted to see the continued progress of Belluscura."
About Belluscura
Belluscura (www.belluscura.com) was established by Tekcapital
with the objective of improving healthcare through innovation. They
are currently developing a proprietary oxygen concentrator system
with a planned commercial release in 2019 that will be used to
deliver supplemental long-term oxygen therapy to patients suffering
from chronic respiratory conditions such as COPD, asthma,
occupational lung diseases and pulmonary hypertension. Tekcapital
owns approximately 29% of Belluscura.
For further information, please contact:
Tekcapital plc Via Yellow Jersey PR
Clifford M Gross, Ph.D.
finnCap Ltd (Nominated
Adviser and Joint Broker) + 44 (0) 20 7220 0500
Geoff Nash / Max Bullen-Smith
(Corporate Finance)
Camille Gochez/Alice
Lane (ECM)
Novum Securities Limited
(Joint Broker) +44 (0) 20 7399 9427
Colin Rowbury (Corporate
Broking)
Yellow Jersey Limited +44 (0) 20 7933 8780
Tim Thompson / Annabel tekcapital@yellowjerseypr.com
Atkins
Tekcapital plc - The World's Largest University Network for Open
Innovation
Tekcapital's objective is to create value from investing in new,
university-developed intellectual properties. Additionally, using
its proprietary discovery search engine, linked to 4,500+
universities in 160 countries, coupled with expert scientific
review, Tekcapital provides a range of IP investment services to
make it easy for organisations to find, evaluate, acquire and
license university-developed technology. Tekcapital plc is quoted
on the AIM market of the London Stock Exchange (AIM: symbol TEK)
and is headquartered in Oxford, in the UK. For more information,
please visit www.tekcapital.com
LEI: 213800GOJTOV19FIFZ85
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
NRAGGUMCPUPBURB
(END) Dow Jones Newswires
February 19, 2019 03:52 ET (08:52 GMT)
Tekcapital (LSE:TEK)
Graphique Historique de l'Action
De Août 2024 à Sept 2024
Tekcapital (LSE:TEK)
Graphique Historique de l'Action
De Sept 2023 à Sept 2024